Abstract
To determine the correlation between changes in sperm DNA methylation levels and sperm parameters and their influence on fertilization rate. A cohort study. A total of 82 human semen samples were collected during the period between March 2016 and September 2016. Samples were obtained from sub-fertile (as a case group), and from fertile males (as a control group). As a pilot study, twenty samples (10 case and 10 controls) were subjected to Infinium 450K BeadChip arrays, to identify genomic regions that differences in sperm DNA methylation patterns in subfertile compared to fertile males who have idiopathic infertility and underwent intracytoplasmic sperm injection (ICSI). Then tow CpGs were validated by local deep bisulfite sequencing on 82 sperm samples (n = 44 subfertile) and (n = 38 fertile). According to the results of pilot study 15 CpGs have been significantly different in the sperm DNA methylation levels between cases compared to controls group. Only 9 CpGs do not have overlap common annotated SNPs. The results of the validation study for the two CpG (cg19779893, cg19406113) found that a significant variation in the methylation level at 2 CpG (CpG2, CpG3) out of 3 CpGs related to cg19779893 site amplicon (P ≤ 0.03, P ≤ 0.01, respectively) in cases compared to controls. Moreover, Six CpGs from eleven CpG3, CpG5, CpG6*, CpG8, CpG9, and CpG10 related to cg19406113 site amplicon (P ≤ 0.009, P ≤ 0.03, P ≤ 0.02, P ≤ 0.03, P ≤ 0.007, and P ≤ 0.02 respectively) showed significant difference in sperm DNA methylation between cases and controls group. Furthermore, significantly decreased was showed in the sperm concentration, motility, morphology, vitality, viability, and fertilization rate (P ≤ 0.04, P ≤ 0.02, P ≤ 0.04, P ≤ 0.003, P ≤ 0.03, and P ≤ 0.04 respectively) in the case compared to control groups. The present study found two CpG altered in sperm DNA methylation levels. In addition, a strong association between changes in sperm DNA methylation levels in these CpG sites and sperm parameters.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
